Corpus Intelligence IC Memo — BROADDUS HOSPITAL ASSOCIATION 2026-04-26 03:50 UTC
IC Memo — BROADDUS HOSPITAL ASSOCIATION
Investment Committee Memorandum | WV | 12 beds | Grade C | EBITDA uplift $1.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BROADDUS HOSPITAL ASSOCIATION

CCN 511300 | BARBOUR, WV | 12 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BROADDUS HOSPITAL ASSOCIATION is a 12-bed suburban community hospital in BARBOUR, WV with $21.2M in net patient revenue and a -0.9% operating margin. The hospital serves a payer mix of 41.7% Medicare, 8.3% Medicaid, and 50.0% commercial.

Thesis: Turnaround. Our ML models identify $1.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.9% to 6.4% (+736bps).

Net Revenue HCRIS$21.2M
Current EBITDA COMPUTED$-194K
Operating Margin COMPUTED-0.9%
Occupancy HCRIS46.3%
Revenue / Bed COMPUTED$1.8M
Net-to-Gross HCRIS80.6%
Distress Probability ML55.1%

2. Market Context & Competitive Position

62
WV Hospitals
-0.3%
State Median Margin
866
Comparable Hospitals

WV has 62 Medicare-certified hospitals with a median operating margin of -0.3%. The target's margin of -0.9% places it below the state median. Among 866 size-comparable peers (6-24 beds), the median margin is -8.5%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (6-24), prioritizing same-state peers. 866 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BROADDUS HOSPITAL ASSOCIATION (Target)WV12$21.2M-0.9%
FRED HUTCHINSON CANCER CENTERWA20$1.17B-50.0%
WENATCHEE VALLEY HOSPITALWA11$277.5M-4.9%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
THE SURGICAL HOSPITAL AT SOUTHOH24$166.6M-3.1%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
NORTON SOUND REGIONAL HOSPITALAK18$148.7M-28.6%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$445K+210bp18mo
Cost to Collect4.5%2.5%$424K+200bp12mo
Denial Rate Reduction12.0%6.5%$420K+198bp12mo
A/R Days Reduction5200.0%3800.0%$258K+122bp9mo
Clean Claim Rate88.0%96.0%$14K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$445K
Cost to Collect
$424K
Denial Rate Reduction
$420K
A/R Days Reduction
$258K
Clean Claim Rate
$14K
Total EBITDA Uplift$1.6M
Current EBITDA$-194K
+ RCM Uplift+$1.6M
Pro Forma EBITDA$1.4M
Current Margin-0.9%
Pro Forma Margin6.4%
WC Released (1x)$814K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-298K$14.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-298K$15.7M0.00x-100.0%
Bull Case9.0x11.0x$-268K$20.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-268K$22.5M0.00x-100.0%
Bear Case11.0x10.0x$-327K$6.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-327K$7.2M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 55.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 866 hospitals with 6-24 beds
  • Same-state prioritization (n=6)
  • Comp margins: P25=-22.6% / P50=-8.5% / P75=2.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.